Zevra Therapeutics, Inc.
ZVRA
$8.02
-$0.195-2.38%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 62.02M | 40.59M | 23.61M | 24.49M | 23.69M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 62.02M | 40.59M | 23.61M | 24.49M | 23.69M |
| Cost of Revenue | 17.39M | 8.59M | 7.42M | 7.28M | 5.12M |
| Gross Profit | 44.63M | 32.00M | 16.20M | 17.21M | 18.57M |
| SG&A Expenses | 72.71M | 64.53M | 54.92M | 54.18M | 43.79M |
| Depreciation & Amortization | 6.39M | 6.32M | 6.24M | 5.39M | 3.85M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 122.43M | 112.47M | 110.62M | 111.23M | 98.49M |
| Operating Income | -60.41M | -71.88M | -87.00M | -86.74M | -74.80M |
| Income Before Tax | 21.40M | -75.37M | -90.14M | -89.66M | -66.63M |
| Income Tax Expenses | 18.75M | 16.62M | 15.37M | 0.00 | 177.00K |
| Earnings from Continuing Operations | 2.64 | -91.99 | -105.51 | -89.66 | -66.81 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.64M | -91.99M | -105.51M | -89.66M | -66.81M |
| EBIT | -60.41M | -71.88M | -87.00M | -86.74M | -74.80M |
| EBITDA | -53.85M | -65.40M | -80.61M | -81.22M | -70.83M |
| EPS Basic | -0.18 | -1.90 | -2.24 | -2.08 | -1.69 |
| Normalized Basic EPS | -0.84 | -0.99 | -1.22 | -1.30 | -1.05 |
| EPS Diluted | -0.21 | -1.90 | -2.24 | -2.09 | -1.69 |
| Normalized Diluted EPS | -0.84 | -0.99 | -1.22 | -1.30 | -1.05 |
| Average Basic Shares Outstanding | 210.16M | 197.28M | 184.96M | 170.20M | 157.12M |
| Average Diluted Shares Outstanding | 211.70M | 197.28M | 184.96M | 170.20M | 157.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |